IMMP News and Press, Immutep Limited From 11/02/21

Immutep (NASDAQ:IMMP) announces the grant of a new patent entitled "use of recombinant LAG-3 or the derivatives thereof for eliciting a monocyte immune response" by the Chinese Patent Office. The patent forms part of a broad portfolio of patent families for the company’s lead prod...

SYDNEY, AUSTRALIA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce ...

Immutep (NASDAQ:IMMP) has received positive feedback from the EMA regarding its clinical development program for lead product candidate, eftilagimod alpha ((efti)), in breast cancer. In its scientific advice the EMA has supported the company’s view to continue the development of e...

Positive feedback for the general clinical development program including the planned registrational Phase III trial in metastatic breast cancer (MBC) Other regulatory engagement ongoing, including with the US Food and Drug Administration (FDA) SYDNEY, AUSTRALIA, Oct. 29, 202...

Received competent authority and institutional review board approvals for TACTI-003 Phase IIb trial Enrolled first patient in INSIGHT-003 study in patients with various solid tumours Preparations progressing for new Phase III trial (AIPAC-003) in metastatic breast cancer Final...

Sydney, Australia, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce ...

SYDNEY, AUSTRALIA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announc...

Sydney, AUSTRALIA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, will present at investor c...

SYDNEY, Australia, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce it will...

Sydney, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Last 2 nd line PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patient has been enrolled and safely dosed, completing recruitment of Stage 2 of Part B Total of 154 patients out of up to 183 patients (84%) now participating in...